Tambe said the company, a subsidiary of the Bengaluru-based Biocon Ltd, has five products in the pipeline for launch in the ...

The efficacy benefits of biphasic insulin aspart formulation (BIAsp 30) in patients with diabetes mellitus have been reported in several studies. BIAsp 30 has been shown to be more effective in ...

The current review has used an EBM approach to evaluate the strength and validity of the evidence supporting the clinical efficacy and tolerability and the administration benefits of insulin ...

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.

Alongside margin recovery, Biocon Biologics has also gained market share, with oncology remaining a key focus area.

The FDA approved its short-acting insulin, Fiasp (insulin aspart injection) in September, and its long-acting insulin Tresiba (insulin degludec) got US approval late last year. [caption id ...

The first round of talks, which yielded prices set to take effect in 2026, included insulin aspart, which Novo sells as several different products. That selection triggered a lawsuit from Novo ...

The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.

The non-profit drugmaker plans to launch biosimilars of Sanofi’s Lantus (insulin glargine), Novo Nordisk’s Novolog (insulin aspart) and Eli Lilly’s Humalog (insulin lispro) by 2024.

Shares of Biocon Ltd climbed 7 per cent in Tuesday's trade, with the nearing its September 2024 high of Rs 395.65, after HSBC upgraded the stock to 'Buy' from 'Reduce' earlier. The foreign ...